Ubrogepant for migraine: how it works and what to expect
Ubrogepant is an oral CGRP receptor antagonist for acute migraine. Find out how it compares to triptans, what the evidence shows, and whether it might work for you.
What ubrogepant is
Ubrogepant is an oral medication that stops migraines by blocking calcitonin gene-related peptide (CGRP) receptors in the brain. It's taken at the first sign of a migraine attack, not as a daily preventive.
How it works
During a migraine, CGRP is released and triggers inflammation and pain signals. Ubrogepant blocks the receptors that CGRP binds to, stopping that cascade before it builds. This is a different mechanism from triptans, which narrow blood vessels.
Effectiveness
Clinical trials show ubrogepant relieves migraine pain within 2 hours in roughly 20-30% more people than placebo. Most people who respond see relief within 2 hours. Sustained relief (staying pain-free for 24 hours) occurs in about 30-40% of users.
Side effects
Common side effects are mild: nausea, drowsiness and dry mouth appear in under 10% of users. Serious side effects are rare.
Cost and access
Ubrogepant is a brand-name drug (Ubrelvy). Without insurance, a single dose costs around $250-300. Most insurance plans cover it; check your formulary to see if it requires prior authorization.
When to use it
Take ubrogepant as soon as migraine pain starts. You can take a second dose if the first doesn't work or pain returns within 2-24 hours, but do not exceed 2 doses in 24 hours.